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INTRODUCTION 
 
Heterocyclic compounds possess considerable attention in recent years 
because of their broad range of pharmaceutical activities.  Among them, Nitrogen 
and Sulphur hetero atoms containing five/six membered heterocyclic compounds 
are found to be of great importance in medicinal applications.  Especially, 1,2,3-
triazole and dihydropyrimidine-2-thione nucleus is found to possess biological 
activities such as antifungal,(Vandana s. Pore et al; 2009) antitubercular (Vitor F 
Ferreira et.al; 2006), antibacterial, (S.Nagarajan et.al; 2012), antiviral (Chi-Huey 
wong et.al., 2003), antimicrobial (Kadir dabak et.al.,2003), antiproliferative 
(Ahamed ajmal et.al.,2008) and cytotoxic agents etc. Hence, chemists/biologists 
are on a continuous pursuit to design and synthesize heterocyclic hybrids over the 
years essentially because of their medicinal importance. 
Computerized conformational analysis used to predict the 3D structure of 
drug with the receptor. QSAR used to elucidate the mechanism of action of drugs at 
the molecular level and physicochemical property like hydrophobicity. (Burger’s)  
1, 2, 3-TRIAZOLE NUCLEUS:     
  
1,2,3-triazole nucleus with three nitrogen atoms and electron rich property has 
been paid special attention in the development of new drugs due to large 
medicinal potentiality of triazole-based derivatives.   These exciting achievements 
encourage continuous efforts to develop of 1, 2, 3- triazole compounds for the 
treatment of infective diseases. Considering the importance of chalcone and 
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triazole compounds, and as an extension of our researches on bioactive 
heterocyclic compounds 
Triazole moiety is able to easily bind with various enzymes and receptors in 
organisms through coordination bonds, hydrogen bonds, ion-dipole, cation-p, pep 
stacking, hydrophobic effect and van der Waals force etc., which helpfully modulate 
the physicochemical and pharmacokinetics properties. 
DIHYDROPYRIMIDINE-2-THIONE:    
  
 On the other hand, dihydropyrimidines has structural resemblance with 
clinically important Hantzsch pyridines.  Also, literature study reveals that the 
pyrimidines exhibit wide range of biological activities viz. antibacterial (S.Nagarajan 
et.al, 2012), anticancer,   antiviral (Shireesha Boyapati et al.,2015), antitumor, 
anti-inflammatory etc.  Moreover, Pyrimidine-2-thiones were found to inhibit the 
synthesis of t-RNA under certain conditions and thus act as anti-tumour and anti-
thyroid agents.  
1,2,3-TRIAZOLE-PYRIMIDINE-2-THIONE HYBRIDS:     
 The utilization of simple molecules with different functionalities is a valuable 
contribution in the chemistry of heterocycles.  Particularly, heterocyclic hybrids are 
single frameworks wherein more than one heterocyclic moieties are being grafted 
with a view of designing more effective and enhance the bioactive entities.  
In view of the above and continuation of our earlier reported work                          
(S.Nagarajan et.al., 2012) we planned to synthesize and explore the hybrid 
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bioactive skeletons viz. 1,2,3-triazole linked pyrimidine-2-thione derivatives via 
green protocol.  Furthermore, all the synthesized hybrids were evaluated docking 
and in-vitro anticancer studies. 
 
 
GREEN CHEMISTRY:  
     
 It is better to prevent waste than to treat or clean up waste after it is formed. 
 Synthetic methods should be designed to maximize the incorporation of all 
materials used in the process into the final product. 
 Wherever practicable, synthetic methodologies should be designed to use 
and generate substances that chemical process little or no toxicity to human 
health and the environment, 
 Chemical products should be designed to preserve efficacy of function while 
reducing toxicity. 
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 The use of auxillary substances (e.g. solvents, separation agents, etc.) 
should be made unnecessary wherever possible and innocuous when used. 
 Energy requirements should be recognised for their environmental and 
economic impacts and should be minimised. Synthetic methods should be 
conducted at ambient temperature and pressure. 
 A raw material or feedstock should be renewable rather than depleting 
wherever technically and economically practicable. 
 Unnecessary derivatization (blocking group, protection / deprotection, 
temporary modification of physical/chemical processes) should be avoided 
wherever possible. 
 Catalytic reagents (as selective as possible) are superior to stoichiometric 
reagents. 
 Chemical products should be designed so that at the end of their function 
they do not persist in the environment and breakdown into innocuous 
degradation products. 
 Analytical methodologies need to be developed further to allow for real-time 
in- process monitoring and control prior to the formation of hazardous 
substances. 
 Substances and the form of a substance used in a chemical process should 
be chosen so as to minimize the potential for chemical accidents, including 
releases, explosions and fires. 
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CONDENSED PRINCIPLES OF GREEN CHEMISTRY         
P - Prevent wastes            
R - Renewable materials           
O -  Omit derivatization steps              
D - Degradable chemical products                          
U    - Use safe synthetic methods            
C - Catalytic reagents              
T - Temperature, Pressure ambient            
I - In-Process Monitoring           
V  -  Very few auxillary substances                     
E - E-factor, maximise feed in product                   
L - Low toxicity of chemical products                     
Y -  Yes, it is safe.       
 
            The broad scope of the greener methodology involving water as media was 
established via the synthesis of a library of 1,2,3-triazolyl dihydropyrimidine-2-thione 
hybrids  in good to excellent yields (79% to 95%) 
 
MOLECULAR DESIGN:  
Various software used in molecular designs are 
 1. CHEM SKETCH 
 2. CHEM DOODLE 
 3.MOLINSPIRATION 
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SPECTROSCOPY: 
Spectroscopy is the branch of science that deals with the study of interaction 
of electromagnetic radiation with matter. 
Spectroscopy is one of the most powerful tools available for the study of 
atomic and molecular structure of organic compounds. (Y.R.Sharma)  
 
I.R spectroscopy: 
 IR spectrum were recorded by absorption of infrared radiation it causes 
changes in vibrational energy in the ground state of the molecule. (Robert 
silverstein)           
NMR spectroscopy: 
Nuclear magnetic resonance(NMR) spectroscopy is a technique that permits 
the transition of a molecule at the level of the individual atom and giving information 
about the environment of that atom (Beckett and stanlake). 
Mass spectroscopy: 
Molecules are bombarded with electrons of sufficient energy, loss of an 
electron and formation of positive ion.It is used to determine the molecular weight of 
the compounds . (Y.R.Sharma) 
. MOLECULAR DOCKING 
Molecular docking provides useful information about drug receptor 
interactions. It analyzes the binding orientation of small molecule drug candidates to 
their protein targets in order to predict the affinity and activity of the small molecule. 
(Mavromoustakosa et.al.,2010) 
  Docking is considered to be a powerful simulation of the molecular 
recognition process. It is used to illustrate the probable molecular interaction of a 
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designed ligand with the protein of interest, predict the affinity and activity of the 
ligand, and identify the energy of the interaction between the ligand and protein. 
DEFINITION 
“Molecular docking may be defined as an optimization problem, which 
would describe the „best-fit‟ orientation of a ligand that binds to a particular protein 
of interest. However, since both the ligand and the protein are flexible, a „hand-in-
glove‟ analogy is more appropriate than „lock-and-key‟.”
 
It is an invaluable tool in the field of molecular biology, computational 
structural biology, computer-aided drug designing, and pharmacogenomics. 
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Aim of docking studies:  
 Accurate structural modeling 
 Correct prediction of activity. 
Steps of ligand docking: 
 Preparation of ligands 
 Preparation of proteins 
 Setup ligand protein docking calculations 
 Evaluation of results 
Classification of docking:  
Based on the types of ligand, docking can be classified as: 
 Protein-small molecule (ligand) docking 
 Protein-nucleic acid docking 
 Protein-protein docking. 
Advantages of docking: 
 The application of docking in a targeted drug-delivery system is a huge 
benefit. One can study the size, shape, charge distribution, polarity, 
hydrogen-bonding, and hydrophobic interactions of both ligand (drug) and 
receptor (target site). 
 It helps in the identification of target sites of the ligand and the receptor 
molecule. 
 It also helps in the understanding of different enzymes and their mechanism 
of action. 
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 The “scoring” feature in docking helps in selecting the best-fit or the best drug 
from an array of options. 
 It has huge advantage when it comes to the study of protein interactions. 
 There are a millions of compounds, ligands, drugs, and receptors, the 3D 
structure of which has been crystallized. Virtual screening of these 
compounds can be made. 
Limitations of docking: 
 In protein-small molecule docking, there can be problems in the receptor 
structure. A reliable resolution value for small- molecule docking is below 1.2  
A, while most crystallographic structures have a resolution between 1.5 and 
2.5 A increasing the use of homology models in docking should be locked at 
with care as they have even poorer resolution. Most applications accept and 
yield good results for structures below 2.2A. All the same, care should be 
taken while picking a structure. 
 The scoring functions used in docking, almost all of them, do not take into 
account the role played by covalently bound inhibitors or ions. 
 The methodology and research in protein-protein docking have to be greatly 
increased as the success in this field is greatly hampered by many false 
positives and false negatives. 
CANCER : 
Cancer is  abnormal multiplication of cells. Cancer is a group of diseases 
involving abnormal cell growth with the potential to invade or spread to other parts 
of the body. These contrast with benign tumours, which do not spread to other parts 
of the body. Possible signs and symptoms include a lump, abnormal bleeding, 
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prolonged cough, unexplained weight loss, and a change in bowel movements. 
While these symptoms may indicate cancer, they may have other causes. Over 100 
types of cancers affect humans. (ASTHOSKAR) 
Tobacco use is the cause of about 22% of cancer deaths. Another 10% are 
due to obesity, poor diet, lack of physical activity, and excessive drinking of alcohol. 
Other factors include certain infections, exposure to ionizing radiation and 
environmental pollutants. In the developing world, 15% of cancers are due to 
infections such as Helicobacter pylori, hepatitis B, hepatitis C, human papillomavirus 
infection, Epstein–Barr virus and human immunodeficiency virus.  
These factors act, at least partly, by changing the genes of a cell. Typically 
many genetic changes are required before cancer develops. Approximately 5–10% 
of cancers are due to inherited genetic defects from a person's parents. Cancer can 
be detected by certain signs and symptoms or screening tests. It is then typically 
further investigated by medical imaging and confirmed by biopsy. 
Many cancers can be prevented by not smoking, maintaining a healthy 
weight, not drinking too much alcohol, eating plenty of vegetables, fruits and whole 
grains, vaccination against certain infectious diseases, not eating too much 
processed and red meat, and avoiding too much sunlight exposure.  Early detection 
through screening is useful for cervical and colorectal cancer.  
The benefits of screening in breast cancer are controversial. Cancer is often 
treated with some combination of radiation therapy, surgery, chemotherapy, and 
targeted therapy. Pain and symptom management are an important part of care. 
Palliative care is particularly important in people with advanced disease. The chance 
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of survival depends on the type of cancer and extent of disease at the start of 
treatment. In children under 15 at diagnosis the five-year survival rate in the 
developed world is on average 80%. For cancer in the United States the average 
five-year survival rate is 66%. 
In 2015, about 90.5 million people had cancer. About 14.1 million new cases 
occur a year (not including skin cancer other than melanoma). It caused about 8.8 
million deaths (15.7% of deaths). The most common types of cancer in males are 
lung cancer, prostate cancer, colorectal cancer and stomach cancer.  In females, 
the most common types are breast cancer, colorectal cancer, lung cancer and 
cervical cancer. 
If skin cancer other than melanoma were included in total new cancers each 
year, it would account for around 40% of cases. In children, acute lymphoblastic 
leukaemia and brain tumours  are most common except in Africa where non-
Hodgkin lymphoma occurs more often.  In 2012, about 165,000 children under 15 
years of age were diagnosed with cancer.  
The risk of cancer increases significantly with age and many cancers occur 
more commonly in developed countries. Rates are increasing as more people live to 
an old age and as lifestyle changes occur in the developing world. The financial 
costs of cancer were estimated at $1.16 trillion USD per year as of 2010. 
(K.D.Tripathi) 
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Mechanism of anti-cancer drugs:       
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 AIM AND OBJECTIVES 
  Generally, Nitrogen and Sulphur hetero atoms containing five/six membered 
heterocyclic compounds are found to be of great importance in medicinal 
applications.  Especially, 1,2,3-triazole and dihydropyrimidine-2-thione nucleus is 
found to possess biological activities.  The utilization of simple molecules with 
different functionalities is a valuable contribution in the chemistry of heterocycles.  
Particularly, heterocyclic hybrids are single frameworks wherein more than one 
heterocyclic moiety is being grafted with a view of designing more effective and 
enhance the bioactive entities.  
In view of the above and continuation of our earlier reported work 
(S.Nagarajan et.al.,2012) , we planned to synthesize and explore the hybrid 
bioactive skeletons viz. 1,2,3-triazole linked pyrimidine-2-thione derivatives via green 
protocol.  Furthermore, all the synthesized hybrids were evaluated docking and in-
vitro anticancer studies. 
Objectives of the study: 
 To design the lead molecule of 1,2,3-triazolyl dihydropyrimidine-2-thione and 
ADMET property. 
 To synthesis the compounds by appropriate methods. 
 To purify the synthesized compound by TLC. 
 To carry out the physical constant like solubility, melting point, etc. 
 To characterize the structures of synthesized compounds by IR,1HNMR and 
Mass spectra.                                  
 To predict the anticancer activity by docking methods. 
 To evaluate the proposed compounds for their in-vitro anti-cancer activity. 
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                    MATERIALS AND METHODS 
 
LISTS OF CHEMICALS USED: 
Table no:1.   
S.No Name of Chemicals Grade Manufacture/Suppliers 
1. Benzyl azide  Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
2. Acetyl acetone 
 
Analytical  
Reagent 
Avra Synthesis Pvt. Ltd. 
3. Potassium carbonate 
 
Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
4. Ethanol 95% 
 
Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
5. 3-methyl benzaldehyde Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
6. 2-chloro benzaldehyde 
 
Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
7. Furfural  Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
8. 2-thiophene carbaldehyde 
 
Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
9. Isopropyl benzaldehyde 
 
Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
10. Sodium hydroxide 50% 
 
Analytical  
Reagent 
Avra Synthesis Pvt. Ltd. 
11. Thiourea  
 
Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
12. Potassium hydroxide 10% 
 
Laboratory 
Reagent 
Avra Synthesis Pvt. Ltd. 
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List of instruments used: 
Table no: 2  
 
 
 
            
 
S.No Name of the 
Instrument 
Model Manufacturer/supplier 
1. UV-Visible spectrophotometer 
 
1800 Shimadzu 
2. Fourier transform IR 
Spectrometer 
 
IR-Affinity-1 Shimadzu 
3. KBr press 
 
M-15 Technosearch 
4. Mass Spectrometer JEOL GC-MATE-
II HR 
Thermo fisher 
5. 
 
NMR Spectrometer Avance 300 MHz  Bruker 
6. Thermostatically controlled water 
bath 
PIC 108 M.C.Dalal 
7. Electronic Balance 
 
M-D4404420019 Shimadzu 
8. Centrifuge 
 
LABO51 Shimadzu 
9. Autoclave 
 
7441 Fajj 145 Equitron 
10. UV-Chamber 
 
CE102A Deep vision 
11. Microwave oven 
 
MS-2029UW Intellowave technology 
12. Incubater 
 
7441 sleudoc Rays 
13. Melting point apparatus 
 
Ce100 Labtronics 
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REACTANT PROFILE: 
                                               BENZALDEHYDE 
                                                           
Appearance  : Flammable liquid and vapour 
Molecular formula  : C7H7N3 
Molecular weight : 133.154g/mol 
Melting point  : 81-83ºC 
Density                    : 1.0655 
Solubility           : Miscible with ethanol and diethyl ether 
 Category           : Pharmaceutical Aid 
 
                                                        ACETYL ACETONE 
 
Appearance                :  Colourless liquid 
Molecular formula       :  C5H8O2 
Molecular weight         :   100.117g/mol 
Boiling  point               :   284.7 ºF 
Melting point               :   -10.3 ºF 
Density                       :    0.975g/mL at 25 ºC 
Solubility                     :     Soluble in water 
Category                     :      Pharmaceutical Aid 
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POTASSIUM CARBONATE 
                                                               K2CO3 
Appearance   : White or Yellow colour powder 
Molecular formula  : CK2O3 
Molecular weight : 138.21g/mol 
Melting point            :  891 ºC  
Density                    :  2.43g/mL at 25 ºC 
Solubility  :  soluble in water 
Category                 :  Pharmaceutical Aid 
 
ETHANOL 
C2H5OH 
Appearance   : Colourless liquid 
Molecular formula  : C2H6O 
Molecular weight : 46.069g/mol 
Melting point  : 114.10C 
Density                    :  789Kg/m3 
Solubility  : Soluble in water. 
Category  : Pharmaceutical Aid. 
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3-METHYL BENZALDEHYDE 
      
Appearance              : Tan to brown crystalline powder 
Molecular formula  :  C8H8O 
Molecular weight : 120.151g/mol 
Melting point  : 118-1200C 
Density                    :  1.0189g/cu cm at 210C 
Solubility  : Slightly soluble in water. 
Category  : Pharmaceutical Aid. 
                       
                                          2-CHLOROBENZALDEHYDE 
 
Appearance   : colourless to light yellow colour liquid 
Molecular formula  : C7H5ClO 
Molecular weight : 140.57g/mol 
Melting point  :  9-11ºC 
Density                    :  1.245g/ml at 250C 
Solubility  : Soluble in alcohol, ether, acetone, benzene.. 
Category  : Pharmaceutical Aid  
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FURFURAL 
 
Appearance   : Colourless to Pale yellow oily liquid 
Molecular formula  :  C5H4O2 
Molecular weight : 96.085g/mol 
Melting point  : -33.7ºF 
Density                    :  1.159 at 680C 
Solubility  : Soluble in water, alcohol, ether. 
Category  : Pharmaceutical Aid. 
                                 
                                   2-THIOPHENE CARBALDEHYDE 
      
Appearance  : Clear yellow  liquid 
 
Molecular Formula  : C5H4OS 
 
Molecular weight : 112.146g/mol 
Melting point  : <10ºC 
Density                    :  1.29g/ml at 250C 
Solubility  : Insoluble in water 
Category  : Pharmaceutical Aid. 
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4-ISOPROPYL BENZALDEHYDE: 
 
Appearance   : Clear colourless liquid 
Molecular formula  :  C10H12O 
Molecular weight : 148.2g/mol 
Boiling point  : 235-236ºC 
Density                    :  0.977g/ml at 250C 
Solubility  : Soluble in ethanol. 
Category  : Pharmaceutical Aid      
            
         
SODIUM HYDROXIDE 
NaOH 
Appearance  : White solid 
Molecular formula  :NaOH 
Molecular weight :39.997g/mol 
Melting  point : 604ºF 
Density                    :  2.13g/cu cm at 250C 
Solubility            : Very Soluble in water, freely soluble in ethanol 
Category  : Pharmaceutical Aid 
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                                                                  THIOUREA: 
                                                                
Appearance    : White crystalline solid 
Molecular formula      :CH4N2S 
Molecular weight : 76.117g/mol 
Melting  point : 349 - 352ºF 
Density  : 1.405 at 68 ºF  
Solubility            : Soluble in water.  
Category  : pharmaceutical Aid 
 
                                                    POTASSIUM HYDROXIDE: 
                                                               KOH 
Appearance    : White solid deliquescent 
Molecular formula      :KOH 
Molecular weight  : 56.105g/mol 
Melting  point : 360ºC 
Density  : 2.12g/cm3 at 25 ºC  
Solubility            : Soluble in water, alcohol, glycerol. 
Category  : pharmaceutical Aid 
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Scheme of the work 
 
Synthesis of 1,2,3-triazolyl dihydropyrimidine-2-thione hybrids 
 
 
 
 
 
Synthesis of a library of 1,2,3-triazolyl dihydropyrimidine-2-thione hybrids 5(a-e) 
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EXPERIMENTAL WORK 
Molecular design: 
                 The software tools like Chemdoodle, Molinspiration, Chemsketch were used 
to study the newly synthesized molecules.  
A) Chemdoodle:  
Lipinski's rule of five also known as the Pfizer's rule of five or simply the Rule of 
five (RO5) is to evaluate drug likeness or determine if a chemical compound with a 
certain pharmacological or biological activity has properties that would make it a likely 
orally active drug in humans. The rule was formulated by Christopher A. Lipinski in 
1997. The rule describes molecular properties important for a drug’s pharmacokinetics 
in the human body, including their absorption, distribution, metabolism, and excretion 
(ADME). However, the rule does not predict if a compound is pharmacologically active.  
Lipinski's rule states that, in general, an orally active drug has no more than one 
Violation of the following criteria:  
 Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with 
one or More hydrogen atoms) 
 Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
 A molecular mass less than 500 daltons. 
 An octanol-water partition coefficient log P not greater than 5. 
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B) Molinspiration:  
Molinspiration, a web based software was used to obtain parameter such as 
MiLogP, TPSA, drug likeness. MiLogP is calculated by the methodology developed by 
Molinspiration as a sum of fragment based assistance and correction factors. MiLogP 
parameter is used to check good permeability across the cell membrane. TPSA is 
related to hydrogen bonding potential of compound. Number of rotatable bonds 
measures molecular flexibility. Molinspiration helps to conform about the Lipinski’s rule 
of five.It helps to study the Drug likeness of compound, and also helps to know about 
the Pharmacokinetics profile of the drug entity, that includes absorption, distribution, 
metabolism and excretion (“ADME”).  
C) Chemsketch:  
  It is a software tool used for the prediction of molecular properties such as 
molecular mass, Log P, molar refractivity, parachor, molar volume, surface 
tension,polarizability and chemical composition. 
D) Chemdraw:          
   it is a software tool used to draw molecular structure, chemical 
name, etc. And also designed for creating advanced chemical structures and analysis, 
you may consider ChemDraw Pro 12.0 or ChemDraw Ultra 12.0. & Advanced drawing 
application that also includes the ability to draw biological structures and pathways, you 
will want to refer to ChemBioDraw Ultra 12.0. ChemBioDraw Ultra 12.0 includes all 
features that are available in the Chem & Bio Draw 12.0 Series and BioDraw Series. 
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SYNTHETIC PROCEDURE: 
General Information 
All chemicals, reagents and solvents are commercially high purity grade 
purchased from Avra Synthesis Pvt. Ltd. and Merck Pvt. Ltd. India.  Silica gel (60-120 
mesh) was used for column chromatographic isolation and purification of the 
compounds synthesized.  1H NMR and 13C NMR spectra were recorded in CDCl3 on 
Bruker Avance 300 MHz spectrometer and the chemical shifts are reported as δ values 
in parts per million (ppm) relative to tetramethylsilane, with coupling constant (J) values 
in Hertz (Hz).  In 1H NMR, the abbreviation of splitting refers as s=singlet, d=doublet, 
and m=multiplet.  13C NMR data are reported with the solvent peak (CDCl3=77.0 MHz) 
as the internal standard.   
Synthesis of 4-acetyl-1-benzyl-1,2,3-triazole (1) 
Chemicals required: 
 Benzyl azide     
 Acetyl acetone              
 Potassium carbonate  
   Ethanol 95%           
`A mixture of benzyl azide, acetyl acetone, potassium carbonate and absolute 
ethanol (95%, 15ml) was taken in a round bottomed flask equipped with stirrer.  The 
reaction mixture was stirred at 75°C for 30 minutes.  The progress of the reaction was 
monitored by TLC.  After the completion of the reaction, the solvent was removed 
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under vacuum and to the residual mass; excess of ice-water was added and 
neutralized with 10% HCl (20ml).  The product was extracted with diethyl ether (20ml) 
and the extract dried over anhydrous sodium sulphate.  Evaporation of the solvent 
gave the crude product, which was purified by column chromatography using pet.ether: 
ethylacetate (98:3) as eluent and recrystallized from absolute ethanol, yield 3.97g 
(82%), m.p. 148ºC. 
 
Compound 5a 
Step1: Synthesis of 1,2,3-Triazolyl chalcone: (3a) 
Chemicals required:  
 4-acetyl 1-benzyl 5-methyl-1,2,3 triazole  
 3-methyl benzaldehyde 
 Sodium hydroxide 50%                                         
A mixture of 4-acetyl-1-benzyl-5-methyl-1,2,3-triazole (1) and 3-methyl 
benzaldehyde (2a) and 50% aqueous sodium hydroxide solution (1 ml) was ground for 
4-7 minutes at room temperature and poured onto excess of crushed ice and 
neutralized with dilute hydrochloric acid.  The chalcone derivatives (3a) precipitated as 
solid, which were filtered and recrystallized from ethanol. Yield: 97-99%.                                       
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Step-2- Synthesis of 1,2,3-Triazolyl dihydropyrimidine-2-thione hybrid-1: (5a) 
Chemicals required:  
 1,2,3 triazolyl chalcone  
 Thiourea                    
 Potassium hydroxide 10%                                         
 Water  
A mixture of ((E)-1-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)- 3-(m-tolyl)prop-2-
en-1-one (3a), thiourea (4)  (1.5 equiv.) and 10 % aq. KOH in water or ethanol (10 ml) 
was refluxed for 30-40 minutes and poured onto excess of crushed ice and neutralized 
with dilute hydrochloric acid.  The precipitated triazolyl dihydropyrimidine-2-thione 
derivatives (5a) were filtered and recrystallized from ethanol. 
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Compound 5b 
Step1: Synthesis of 1,2,3-Triazolyl chalcone: (3b) 
Chemicals required:  
 4-acetyl 1-benzyl 5-methyl-1,2,3 triazole  
 Isopropyl benzaldehyde 
 Sodium hydroxide 50%                                         
A mixture of 4-acetyl-1-benzyl-5-methyl-1,2,3-triazole (1) and Isopropyl 
benzaldehyde (2b) and 50% aqueous sodium hydroxide solution (1 ml) was ground for 
4-7 minutes at room temperature and poured onto excess of crushed ice and 
neutralized with dilute hydrochloric acid.  The chalcone derivatives (3b) precipitated as 
solid, which were filtered and recrystallized from ethanol. Yield: 97-99%.                                       
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Step-2- Synthesis of 1,2,3-Triazolyl dihydropyrimidine-2-thione hybrid-1: (5b) 
Chemicals required:  
 1,2,3 triazolyl chalcone  
 Thiourea                    
 Potassium hydroxide 10%                                         
 Water  
A mixture of (E)-1-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-3-(4-
isopropylphenyl)prop-2-en-1-one  (3b), thiourea (4)  (1.5 equiv.) and 10 % aq. KOH in 
water or ethanol (10 ml) was refluxed for 30-40 minutes and poured onto excess of 
crushed ice and neutralized with dilute hydrochloric acid.  The precipitated triazolyl 
dihydropyrimidine-2-thione derivatives (5b) were filtered and recrystallized from 
ethanol. 
 
 
 
 
CHAPTER VI                                                             EXPERIMENTAL WORK 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY,MMC,MDU Page 38 
 
Compound 5c 
Step1: Synthesis of 1,2,3-Triazolyl chalcone: (3c) 
Chemicals required:  
 4-acetyl 1-benzyl 5-methyl-1,2,3 triazole  
 2-Chloro benzaldehyde 
 Sodium hydroxide 50%                                         
A mixture of 4-acetyl-1-benzyl-5-methyl-1,2,3-triazole (1) and 2-Chloro 
benzaldehyde (2c) and 50% aqueous sodium hydroxide solution (1 ml) was ground for 
4-7 minutes at room temperature and poured onto excess of crushed ice and 
neutralized with dilute hydrochloric acid.  The chalcone derivatives (3c) precipitated as 
solid, which were filtered and recrystallized from ethanol. Yield: 97-99%.                                       
Step-2- Synthesis of 1,2,3-Triazolyl dihydropyrimidine-2-thione hybrid-1: (5c) 
Chemicals required:  
 1,2,3 triazolyl chalcone  
 Thiourea                    
 Potassium hydroxide 10%                                         
 Water  
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A mixture of ((E)-1-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-3-(2-
chlorophenyl)prop-2-en-1-one  (3c), thiourea (4)  (1.5 equiv.) and 10 % aq. KOH in 
water or ethanol (10 ml) was refluxed for 30-40 minutes and poured onto excess of 
crushed ice and neutralized with dilute hydrochloric acid.  The precipitated triazolyl 
dihydropyrimidine-2-thione derivatives (5c) were filtered and recrystallized from 
ethanol. 
 
Compound 5d 
Step1: Synthesis of 1,2,3-Triazolyl chalcone: (3d) 
Chemicals required:  
 4-acetyl 1-benzyl 5-methyl-1,2,3 triazole  
 Furfural               
 Sodium hydroxide 50%                                         
A mixture of 4-acetyl-1-benzyl-5-methyl-1,2,3-triazole (1) and furfural (2d) and 
50% aqueous sodium hydroxide solution (1 ml) was ground for 4-7 minutes at room 
temperature and poured onto excess of crushed ice and neutralized with dilute 
hydrochloric acid.  The chalcone derivatives (3d) precipitated as solid, which were 
filtered and recrystallized from ethanol. Yield: 97-99%.                                       
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Step-2- Synthesis of 1,2,3-Triazolyl dihydropyrimidine-2-thione hybrid-1: (5d) 
Chemicals required:  
 1,2,3 triazolyl chalcone  
 Thiourea                    
 Potassium hydroxide 10%                                         
 Water  
A mixture of (E)-1-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)- 3-(furan-2-yl)prop-2-
en-1-one (3d), thiourea (4)  (1.5 equiv.) and 10 % aq. KOH in water or ethanol (10 ml) 
was refluxed for 30-40 minutes and poured onto excess of crushed ice and neutralized 
with dilute hydrochloric acid.  The precipitated triazolyl dihydropyrimidine-2-thione 
derivatives (5d) were filtered and recrystallized from ethanol. 
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Compound 5e 
Step1: Synthesis of 1,2,3-Triazolyl chalcone: (3e) 
Chemicals required:  
 4-acetyl 1-benzyl 5-methyl-1,2,3 triazole  
 Thiophene 2 carboxaldehyde  
 Sodium hydroxide 50%                                         
A mixture of 4-acetyl-1-benzyl-5-methyl-1,2,3-triazole (1) and    Thiophene 2 
carboxaldehyde (2e) and 50% aqueous sodium hydroxide solution (1 ml) was ground 
for 4-7 minutes at room temperature and poured onto excess of crushed ice and 
neutralized with dilute hydrochloric acid.  The chalcone derivatives (3e) precipitated as 
solid, which were filtered and recrystallized from ethanol. Yield: 97-99%.                                       
Step-2- Synthesis of 1,2,3-Triazolyl dihydropyrimidine-2-thione hybrid-1: (5e) 
Chemicals required:  
 1,2,3 triazolyl chalcone  
 Thiourea                    
 Potassium hydroxide 10%                                         
 Water  
CHAPTER VI                                                             EXPERIMENTAL WORK 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY,MMC,MDU Page 42 
 
A mixture of (E)-1-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)- 3-(thiophen-2-
yl)prop-2-en-1-one (3e), thiourea (4)  (1.5 equiv.) and 10 % aq. KOH in water or 
ethanol (10 ml) was refluxed for 30-40 minutes and poured onto excess of crushed ice 
and neutralized with dilute hydrochloric acid.  The precipitated triazolyl 
dihydropyrimidine-2-thione derivatives (5e) were filtered and recrystallized from 
ethanol. 
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RESULTS AND DISCUSSION 
An efficient synthesis of novel 1,2,3 - triazolyl dihydropyrimidine-2-thione 
hybrids has been described in a green protocol.  Furthermore, all the synthesized 
hybrids were evaluated docking and in-vitro anticancer studies.  
Synthesis of 1,2,3-triazolyl dihydropyrimidine-2-thione hybrids: 
 
Synthesis of 1,2,3 - triazolyl dihydropyrimidine-2-thione hybrids 
Purification: 
               All the synthesized compounds were purified by thin layer 
chromatography. The final product was confirmed by TLC using various mobile 
phases such as N- Hexane: ethyl acetate (8;2) chloroform: methanol (1:9) 
Petroleum ether : ethyl acetate (7:3).The spots were identified by iodine chamber 
and UV chamber. 
Physical data: 
 The synthesized compounds physical data such as melting point, solubility 
were determined. The synthesized compounds were soluble in DMSO, ethanol and 
methanol. Melting points of the compounds were determined by open capillary tube 
method with aid of melting point instrument. 
 
Infrared spectroscopy: 
 The IR spectra of the synthesized compounds were recorded on a Fourier 
Transform IR spectrometer (Shimadzu) in the range 4000-400 cm-1 by KBr pellet 
technique and the values are reported.  
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 The synthesized compounds show the absorption in the region around 3050-
3070 presence of aromatic C=H stretching vibrations. The bands around 3200 - 
3500 presence of N-H stretching vibration. The absorption band between 1590 -
1612 indicates the presence of C=N stretching vibrations. The absorption peak 
present in the range 800-900 indicates the presence of SO2NH2. The absorption 
band around 1220-1280 indicates the presence of C-N stretching vibration.  
All the relevant functional group bands were observed for all synthesized 
compounds. (Sharma.Y.R.,4th edition). 
 
Nuclear Magnetic resonance spectroscopy: 
 The natures of proton of all the synthesized compounds were confirmed by 
1HNMRspectroscopy. 
 The 1H-NMR spectra were recorded on Bruker-NMR 400 MHz using DMSO 
as Solvent. The data are given in parts per million (ppm) and are referenced to an 
internal standard of tetra methyl silane (TMS,δ 0.00 ppm). Peak Multiplicity is 
reported as s (singlet), d (doublet), dd (double doublet), t (triplet), and m (multiplet). 
The synthesized compounds of M.D.B1-M.D.B7 show the multiplet peak 
around 6-8 ppm confirms the presence of Aromatic hydrogen. The chemical shift 
value around 3-5ppm confirms the N-H proton. The chemical shift value 2-3ppm  
confirm the presence of aliphatic proton. 
 The relative functional group proton peaks were observed for all the 
synthesized compounds. (A.H.Beckett.,4th edition) 
Mass spectroscopy: 
 The molecular weight of the synthesized compounds were determined by 
mass spectroscopy. All the synthesized compounds were shown corresponding 
molecular ion peak according to their mass.( Sharma .Y.R,2nd edition)  
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ANALYTICAL DATA OF HYBRID-5a 
 
Chemical Formula :  C21H21N5S 
Exact Mass  :  375.15 
Molecular Weight :  375.49 
IUPAC Name :  6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(m-tolyl)-    
                3,4-dihydropyrimidine-2(1H)-thione 
Description  : cream coloured solid 
Solubility : soluble in dichloromethane, dimethyl formamide, 
                                            Dimethyl sulfoxide   
 
3D VIEW OF 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(m-tolyl)-3,4-                       
dihydropyrimidine-2(1H)-thione         
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Chemsketch:  
           
 Molecular Formula   = C21H21N5S 
Formula Weight  = 375.48994 
Composition   = C(67.17%) H(5.64%) N(18.65%) S(8.54%) 
Molar Refractivity  = 112.26 ± 0.5 cm3 
Molar Volume  = 293.0 ± 7.0 cm3 
Parachor   = 772.9 ± 8.0 cm3 
Index of Refraction  = 1.691 ± 0.05 
Surface Tension  = 48.3 ± 7.0 dyne/cm 
Density   = 1.28 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 44.50 ± 0.5 10-24cm3 
Monoisotopic Mass  = 375.151766 Da 
Nominal Mass  = 375 Da 
Average Mass  = 375.4899 Da 
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Molinspiration: 
 
 
 
Molinspiration property engine 
v2016.10 
miLogP         3.97 
TPSA           54.77 
natoms         27 
MW             375.50 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          4 
volume         339.91 
 
 
 
Molinspiration bioactivity score v2016.03 
GPCR ligand                    - 0.42 
Ion channel modulator      - 0.43 
Kinase inhibitor                 - 0.66 
Nuclear receptor ligand    - 0.76 
Protease inhibitor             - 0.66 
Enzyme inhibitor               - 0.45 
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Chemdoodle:  
Hydrogen bond acceptor :  5         
Hydrogen bond donor  :  4 
Degree of unsaturation :  4 
Ring count   :  4 
Rotatable bonds  :  4 
Molecular mass  :  395.6517 U 
Monoisotopic mass  :  395.3083 U 
Boiling point   :  988.82 K 
Melting point   :  786.24 K 
Critical pressure  :  15.90 bar 
Critical volume  :  1166.50 cm3/mol 
Critical temperature  :  1262.17 K 
Molar refractivity  :  118.574 cm3/mol 
TPSA    :  90.160 A2 
XPlogV2.0   :  4.844 
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ANALYTICAL DATA OF HYBRID-5b 
 
Chemical Formula :  C18H17N5S 
Exact Mass  :  403.545        
Molecular Weight :  403.54 
IUPAC Name :  6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(phenyl-4-   
  isopropyl)-3,4-dihydropyrimidine-2(1H)-thione 
Description  : pale brown coloured solid 
Solubility : Soluble in dichloromethane, dimethyl formamide, 
                                            Dimethyl sulfoxide                            
3D view of 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(phenyl-4-isopropyl)-
3,4-dihydropyrimidine-2(1H)-thione 
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Chemsketch: 
Molecular Formula   = C23H25N5S 
Formula Weight   = 403.5431 
Composition    = C(68.46%) H(6.24%) N(17.35%) S(7.95%) 
Molar Refractivity   = 121.29 ± 0.5 cm3 
Molar Volume   = 324.2 ± 7.0 cm3 
Parachor    = 842.6 ± 8.0 cm3 
Index of Refraction   = 1.671 ± 0.05 
Surface Tension   = 45.5 ± 7.0 dyne/cm 
Density    = 1.24 ± 0.1 g/cm3 
Dielectric Constant   = Not available 
Polarizability    = 48.08 ± 0.5 10-24cm3 
Monoisotopic Mass   = 403.183066 Da 
Nominal Mass   = 403 Da 
Average Mass   = 403.5431 Da      
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Molinspiration: 
 
 
 
 
Molinspiration bioactivity score v2016.03 
GPCR ligand                      -0.37 
Ion channel modulator       -0.36 
Kinase inhibitor                  -0.62 
Nuclear receptor ligand      -0.65 
Protease inhibitor               -0.60 
Enzyme inhibitor                -0.38 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Molinspiration property 
engine v2016.10 
miLogP         5.06 
TPSA           54.77 
natoms         29 
MW              403.56 
nON             5 
nOHNH        2 
nviolations    1 
nrotb             5 
volume         373.30 
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Chemdoodle:  
Hydrogen bond acceptor :  2         
Hydrogen bond donor  :  2 
Degree of unsaturation :  14 
Ring count   :  4 
Rotatable bonds  :  5 
Molecular mass  :  403.5451 U 
Monoisotopic mass  :  403.1830                                                                              
Boiling point   :  1040.45 K 
Melting point   :  831.25 K 
Critical pressure  :  18.52 bar 
Critical volume  :  1107.50 cm3/mol 
Critical temperature  :  1319.17 K 
Molar refractivity  :  1231.190 cm3/mol 
TPSA    :  86.860 A2 
XPlogV2.0   :  3.639 
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ANALYTICAL DATA OF HYBRID-5c 
 
Chemical Formula :  C20H18ClN5S 
Exact Mass  :  395.9095  
Molecular Weight :  395.91 
IUPAC Name :  6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2- 
  chlorophenyl)-3,4-dihydropyrimidine-2(1H)-thione 
Description  : white coloured solid 
Solubility : soluble in dichloromethane, dimethyl formamide, 
                                          Dimethylsulfoxide   
3D view of 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-3,4 
dihydropyrimidine-2(1H)-thione 
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Chemsketch:           
Molecular Formula  = C20H18ClN5S 
Formula Weight  = 395.90842 
Composition   = C(60.67%) H(4.58%) Cl(8.95%) N(17.69%) S(8.10%) 
Molar Refractivity  = 112.43 ± 0.5 cm3 
Molar Volume  = 287.1 ± 7.0 cm3 
Parachor   = 770.6 ± 8.0 cm3 
Index of Refraction  = 1.711 ± 0.05 
Surface Tension  = 51.8 ± 7.0 dyne/cm 
Density   = 1.37 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 44.57 ± 0.5 10-24cm3 
Monoisotopic Mass  = 395.097143 Da 
Nominal Mass  = 395 Da 
Average Mass  = 395.9084 Da 
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Molinspiration:           
 
 
Molinspiration property engine 
v2016.10 
miLogP         4.18 
TPSA            54.77 
natoms          27 
MW               395.92 
nON               5 
nOHNH          2 
nviolations      0 
nrotb               4 
volume            336.88 
 
 
 
 
 
 
 
 
Molinspiration bioactivity score v2016.03 
GPCR ligand                     - 0.42 
Ion channel modulator      - 0.42 
Kinase inhibitor                 - 0.74 
Nuclear receptor ligand     - 0.74 
Protease inhibitor              - 0.73 
Enzyme inhibitor               - 0.48 
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Chemdoodle:  
Hydrogen bond acceptor :  2         
Hydrogen bond donor  :  2 
Degree of unsaturation :  14 
Ring count   :  4 
Rotatable bonds  :  4 
Molecular mass  :  395.9095 U 
Monoisotopic mass  :  395.0970 U 
Boiling point   :  1009.68 K 
Melting point   :  842.36 K 
Critical pressure  :  23.09 bar 
Critical volume  :  994.50 cm3/mol 
Critical temperature  :  1300.93 K 
Molar refractivity  :  114.190 cm3/mol 
TPSA    :  86.860 A2 
XPlogV2.0   :  3.489 
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ANALYTICAL DATA OF HYBRID-5d 
 
Chemical Formula :  C18H17N5OS 
Exact Mass  :  351.4278  
Molecular Weight :  351.43 
IUPAC Name :  6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(furan-2-yl)- 
                     3,4-dihydropyrimidine-2(1H)-thione 
Description  : cream coloured solid 
Solubility : soluble in dichloromethane, dimethyl formamide,         
                                          Dimethyl sulfoxide   
 3D view of 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(furan-2-yl)-3,4-
dihydropyrimidine-2(1H)-thione                                                                                                                                                       
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Chemsketch:           
Molecular Formula  = C18H17N5OS 
Formula Weight  = 351.42548 
Composition   = C(61.52%) H(4.88%) N(19.93%) O(4.55%) S(9.12%) 
Molar Refractivity  = 100.00 ± 0.5 cm3 
Molar Volume  = 252.2 ± 7.0 cm3 
Parachor   = 683.7 ± 8.0 cm3 
Index of Refraction  = 1.723 ± 0.05 
Surface Tension  = 54.0 ± 7.0 dyne/cm 
Density   = 1.39 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 39.64 ± 0.5 10-24cm3 
Monoisotopic Mass  = 351.11538 Da 
Nominal Mass  = 351 Da 
Average Mass  = 351.4255 Da 
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Molinspiration: 
 
 
Molinspiration property engine 
v2016.10 
miLogP         2.80 
TPSA            67.91 
natoms          25 
MW               351.44 
nON               6 
nOHNH          2 
nviolations      0 
nrotb               4 
volume           304.92 
 
 
 
 
 
 
 
 
Molinspiration bioactivity score v2016.03 
GPCR ligand                      -0.51 
Ion channel modulator       -0.62 
Kinase inhibitor                  -0.89 
Nuclear receptor ligand     -0.90 
Protease inhibitor              -0.89 
Enzyme inhibitor               -0.53 
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Chemdoodle:  
Hydrogen bond acceptor :  3         
Hydrogen bond donor  :  2 
Degree of unsaturation :  13 
Ring count   :  4 
Rotatable bonds  :  4 
Molecular mass  :  351.4278 U 
Monoisotopic mass  :  351.1153 U 
Boiling point   :  945.03 K 
Melting point   :  806.71 K 
Critical pressure  :  27.50 bar 
Critical volume  :  876.50 cm3/mol 
Critical temperature  :  1234.01 K 
Molar refractivity  :  101.415 cm3/mol 
TPSA    :  100.000 A2 
XPlogV2.0   :  1.771       
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ANALYTICAL DATA OF HYBRID-5e 
 
Chemical Formula :  C18H17N5S2 
Exact Mass  :  367.4964 
Molecular Weight :  367.49 
IUPAC Name :  6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(thiophen-2- 
  yl)-3,4-dihydropyrimidine-2(1H)-thione 
 
Description  : Pale yellow coloured solid 
Solubility : soluble in dichloromethane, dimethyl formamide,     
                                          dimethyl sulfoxide        
3D view of 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(thiophen-2-yl)-3,4-
dihydropyrimidine-2(1H)-thione 
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Chemsketch:          
  
Molecular Formula  = C18H17N5S2 
Formula Weight  = 367.49108 
Composition   = C(58.83%) H(4.66%) N(19.06%) S(17.45%) 
Molar Refractivity  = 106.42 ± 0.5 cm3 
Molar Volume  = 260.2 ± 7.0 cm3 
Parachor   = 714.1 ± 8.0 cm3 
Index of Refraction  = 1.753 ± 0.05 
Surface Tension  = 56.7 ± 7.0 dyne/cm 
Density   = 1.41 ± 0.1 g/cm3 
Dielectric Constant  = Not available 
Polarizability   = 42.19 ± 0.5 10-24cm3 
Monoisotopic Mass  = 367.092536 Da 
Nominal Mass  = 367 Da 
Average Mass  = 367.4911 Da 
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Molinspiration: 
 
 
 
 
Molinspiration property engine 
v2016.10 
miLogP         3.44 
TPSA           54.77 
natoms         25 
MW             367.50 
nON            5 
nOHNH          2 
nviolations    0 
nrotb          4 
volume         314.06 
 
 
 
 
 
 
 
 
Molinspiration bioactivity score v2016.03 
GPCR ligand                     - 0.51 
Ion channel modulator      - 0.60 
Kinase inhibitor                 - 0.81 
Nuclear receptor ligand    - 0.90 
Protease inhibitor             - 0.78 
Enzyme inhibitor               - 0.47 
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Chemdoodle:  
Hydrogen bond acceptor :  2         
Hydrogen bond donor  :  2 
Degree of unsaturation :  13 
Ring count   :  4 
Rotatable bonds  :  4 
Molecular mass  :  367.4964 U 
Monoisotopic mass  :  367.0925 U 
Boiling point   :  965.91 K 
Melting point   :  863.59 K 
Critical pressure  :  27.58 bar 
Critical volume  :  901.50 cm3/mol 
Critical temperature  :  1266.58 K 
Molar refractivity  :  107.367 cm3/mol 
TPSA    :  115.100 A2 
XPlogV2.0   :  1.560          
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Spectral Data 
NMR 
6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(m-tolyl)-3,4-dihydropyrimidine-2(1H)-thione 
(5a) 
 
White solid; m.p.176 °C; Yield: 89%; 
1
H NMR (300 MHz, CDCl3): δ 8.59 (s, 1H), 7.48 – 7.01 
(m, 9H), 6.73 (s, 1H), 5.50 (s, 2H), 5.22 (d, J = 3.3 Hz, 1H), 5.07 (d, J = 1.9 Hz, 1H), 2.33 (s, 
3H), 2.20 (s, 3H). 
 13
C NMR (75 MHz, CDCl3): δ 175.33, 139.53, 138.62, 137.43, 134.16, 
130.37, 129.83, 129.62, 129.14, 129.05, 128.98, 128.58, 127.32, 127.10, 126.81, 126.11, 99.63, 
56.66, 52.18, 21.10, 9.52 
6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(4-isopropylphenyl)-3,4-dihydropyrimidine-
2(1H)-thione (5b) 
 
White solid; m.p.173 °C; Yield: 90%;  
1
H NMR (300 MHz, CDCl3): δ 8.61 (s, 1H), 7.38 – 7.30 
(m, 3H), 7.30 – 7.22 (m, 4H), 7.18 – 7.11 (m, 2H), 6.65 (s, 1H), 5.52 (s, 2H), 5.24 (d, J = 1.8 Hz, 
1H), 5.10 (d, J = 1.8 Hz, 1H), 2.96 – 2.79 (m, 1H), 2.22 (s, 3H), 1.25 (s, 3H), 1.22 (s, 3H).   13C 
NMR (75 MHz, CDCl3): δ 174.85, 149.42, 139.72, 137.32, 136.80, 134.06, 133.92, 130.41, 
129.04, 128.92, 128.48, 127.12, 127.03, 126.87, 125.90, 99.61, 56.42, 52.07, 33.76, 23.85, 9.51.   
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6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-3,4-dihydropyrimidine-
2(1H)-thione (5c) 
 
White solid; m.p.198 °C; Yield: 87%; 
1
H NMR (300 MHz, CDCl3): δ 8.66 (s, 1H), 7.50 (d, J = 
7.6 Hz, 1H), 7.41 – 7.23 (m, 6H), 7.21 – 7.10 (m, 2H), 6.88 (s, 1H), 5.72 (d, J = 4.0 Hz, 1H), 
5.52 (s, 2H), 5.26 (d, J = 3.7 Hz, 1H), 2.25 (s, 3H). 
13
C NMR (75 MHz, CDCl3): δ 175.58, 
139.05, 137.06, 133.96, 133.78, 131.20, 130.56, 129.68, 129.41, 128.96, 128.73, 128.67, 128.43, 
127.79, 127.01, 126.70, 97.41, 52.93, 51.99, 9.45.   
6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(furan-2-yl)-3,4-dihydropyrimidine-2(1H)-
thione (5d) 
 
White solid; m.p.186 °C; Yield: 88%; 
1
H NMR (300 MHz, CDCl3): δ 8.64 (s, 1H), 7.46 – 7.28 
(m, 5H), 7.17 (s, 2H), 6.32 (d, J = 12.8 Hz, 2H), 5.53 (s, 2H), 5.40 – 5.13 (m, 2H), 2.28 (s, 3H).  
13
C NMR (75 MHz, CDCl3): δ 175.65, 155.21, 153.57, 151.62, 145.53, 134.10, 132.96, 129.12, 
128.57, 128.13, 127.12, 124.68, 107.25, 106.13, 95.75, 53.75, 52.16, 9.50.   
6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(thiophen-2-yl)-3,4-dihydropyrimidine-2(1H)-
thione (5e) 
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Light yellow; m.p.185 °C; Yield: 89%.  
1
H NMR (300 MHz, CDCl3): δ 8.64 (s, 1H), 7.40 – 6.94 
(m, 9H), 5.69 – 5.11 (m, 4H), 2.27 (s, 3H).  13C NMR (75 MHz, CDCl3): δ 174.13, 146.53, 
136.86, 133.77, 133.51, 130.51, 128.52, 127.93, 126.64, 126.53, 126.28, 126.16, 125.38, 124.55, 
98.75, 51.44, 50.39, 8.86.   
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1
H NMR (300 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(m-tolyl)-3,4-
dihydropyrimidine-2(1H)-thione (5a) 
 
13
C NMR (75 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(m-tolyl)-3,4-
dihydropyrimidine-2(1H)-thione (5a) 
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1
H NMR (300 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(4-
isopropylphenyl)-3,4-dihydropyrimidine-2(1H)-thione (5b) 
 
13
C NMR (75 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(4-isopropylphenyl)-
3,4-dihydropyrimidine-2(1H)-thione (5b) 
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1
H NMR (300 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-
3,4-dihydropyrimidine-2(1H)-thione (5c) 
 
13
C NMR (75 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-
3,4-dihydropyrimidine-2(1H)-thione (5c) 
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1
H NMR (300 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(furan-2-yl)-3,4-
dihydropyrimidine-2(1H)-thione (5d) 
 
13
C NMR (75 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(furan-2-yl)-3,4-
dihydropyrimidine-2(1H)-thione (5d) 
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1
H NMR (300 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(thiophen-2-yl)-3,4-
dihydropyrimidine-2(1H)-thione (5e) 
 
13
C NMR (75 MHz, CDCl3): 6-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(thiophen-2-yl)-3,4-
dihydropyrimidine-2(1H)-thione (5e) 
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FT-IR 
Hybrid-5a 
 
 
 
STANDARD REGION 
(wave number) 
OBSERVED REGION 
(wave number)  
FUNCTIONAL GROUP 
STRETCHING 
3500-3100 cm-1 3419 cm-1 N-H Stretching 
3150-3020 cm-1 3064 cm-1 C-H Aromatic 
3050-2950 cm-1 3032 cm-1 Mono Substituted Benzene 
3050-2950  cm-1 3032 cm-1 Di substituted Benzene 
3050-2950 cm-1 2953 cm-1 C=CH Stretching 
1400-1300 cm-1 1427 cm-1 C=S Stretching 
1300-950 cm-1 1072 cm-1 C-N Stretching 
 
 
 
 
400600800100014001800240032004000
1/cm
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3
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2
3
.9
5
3
5
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.7
9
3
3
8
1
.2
1
3
3
3
6
.8
5
3
3
2
7
.2
1
3
2
9
6
.3
5
3
1
9
6
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Hybrid-5b  
 
 
 
STANDARD REGION 
(wave number) 
OBSERVED REGION 
(wave number)  
FUNCTIONAL GROUP 
STRETCHING 
3500-3100 cm-1 3417 cm-1 N-H Stretching 
3150-3020 cm-1 3120 cm-1 C-H Aromatic 
3050-2950 cm-1 3053 cm-1 Mono Substituted Benzene 
3050-2950  cm-1 2926 cm-1 Di substituted Benzene 
3050-2950 cm-1 2926 cm-1 C=CH Stretching 
1400-1300 cm-1 1327 cm-1 C=S Stretching 
1300-950 cm-1 1176 cm-1 C-N Stretching 
 
 
 
400600800100014001800240032004000
1/cm
50
60
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80
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100
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7
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6
2
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9
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7
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2
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5
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9
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3
.7
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9
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8
0
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7
4-isopropyl benzaldehde
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Hybrid-5c 
 
 
 
STANDARD REGION 
(wave number) 
OBSERVED REGION 
(wave number)  
FUNCTIONAL GROUP 
STRETCHING 
3500-3100 cm-1 3419 cm-1 N-H Stretching 
3150-3020 cm-1 3064 cm-1 C-H Aromatic 
3050-2950 cm-1 3032 cm-1 Mono Substituted Benzene 
3050-2950  cm-1 3032 cm-1 Di substituted Benzene 
3050-2950 cm-1 2953 cm-1 C=CH Stretching 
1400-1300 cm-1 1288 cm-1 C=S Stretching 
1300-950 cm-1 1251 cm-1 C-N Stretching 
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Hybrid-5d 
 
 
 
STANDARD REGION 
(wave number) 
OBSERVED REGION 
(wave number)  
FUNCTIONAL GROUP 
STRETCHING 
3500-3100 cm-1 3460 cm-1 N-H Stretching 
3150-3020 cm-1 3122 cm-1 C-H Aromatic 
3050-2950 cm-1 3122 cm-1 Mono Substituted Benzene 
3050-2950  cm-1 3122 cm-1 Di substituted Benzene 
3050-2950 cm-1 2953 cm-1 C=CH Stretching 
1400-1300 cm-1 1311 cm-1 C=S Stretching 
1300-950 cm-1 1178 cm-1 C-N Stretching 
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Hybrid-5e 
 
 
STANDARD REGION 
(wave number) 
OBSERVED REGION 
(wave number)  
FUNCTIONAL GROUP 
STRETCHING 
3500-3100 cm-1 3417 cm-1 N-H Stretching 
3150-3020 cm-1 3184 cm-1 C-H Aromatic 
3050-2950 cm-1 3184 cm-1 Mono Substituted Benzene 
3050-2950  cm-1 3064 cm-1 Di substituted Benzene 
3050-2950 cm-1 3064 cm-1 C=CH Stretching 
1400-1300 cm-1 1359 cm-1 C=S Stretching 
1300-950 cm-1 1286 cm-1 C-N Stretching 
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MASS 
Hybrid-5a 
 
MASS: (m/z value):375.50 M+1 ion peak 
Hybrid-5b 
 
MASS: (m/z value):403.56 M+1 ion peak 
CHAPTER-VII a                                                                      SPECTRAL DATA 
 
DEPARTMENT OF PHARMACEUTICAL CHEMISTRY, MMC, MDU. Page 80 
 
Hybrid-5c 
 
MASS: (m/z value):395.92 M+1 ion peak 
Hybrid-5d  
 
MASS: (m/z value):351.48 M+1 ion peak 
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Hybrid-5e 
 
 
MASS: (m/z value):367.50 M+1 ion peak                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
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MOLECULAR DOCKING 
 
Insilico Molecular Docking studies  
Preparation of Protein structure  
Protein target was downloaded from database Protein Data Bank (PDB). 
DNA Topoisomerase is PDB identification is rcsb PDB 1JY1 of the target protein. 
All water molecules were removed and on final stage hydrogen atoms were added 
to receptor molecule. Protein structure homology modeling was done using Swiss 
Model.  
Preparation of Ligands  
Review of Literature show that 1,2,3- triazolyl dihydropyrimidine-2-thione 
contains wide spectrum of activity. Hence it was decided to design a newer 
heterocyclic compound of series hybrid (5a-5e) containing 1,2,3-triazolyl 
dihydropyrimidine-2-thione. 
The ligands were drawn in Chemsketch freeware assigned with proper 2D 
orientation and they are converted in to Three – Dimensional structure using 
CHEM DRAW. All the compounds from hybrid (5a-5e)  were subjected to evaluate 
their compliance for Lipinski’s rule of five.  
All the newly designed compounds were found in compliance with Lipinski’s 
rule of five recommendations for new chemical entity to have good oral 
bioavailability with no violations. The miLogP value of all compounds were found 
below five, suggesting that the molecules have good permeability across the cell 
membrane which in turn is needed for generation of bioactivity.  
Number of violations for all the compounds is zero; it means all newly 
designed compounds will easily bind to receptors. All the compounds hybrid (5a-
5e) are within the limit, that is, 1600A in respect of Topological Polar Surface Area 
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(TPSA), which showed that molecules are fulfilling the optimal requirement for drug 
absorption. The values are tabulated in the (Table. 1 and 2) given below. Hence, all 
the newly designed heterocylic compounds which satisfy Lipinski’s rule and drug 
likeness property has  been taken as a lead for anti-cancer drug targeting protein 
kinase receptor.  
Energy of the molecules was minimized using Dundee PRODRG2 server. 
The energy minimized compounds were then read as input for AutoDock 4.0, in 
order to carry out the docking simulation. (G.Krishnamoorthy et.al 2017)  
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Swiss target prediction report of compound 5a 
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Swiss target prediction report of compound 5b 
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Swiss target prediction report of compound 5c 
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Swiss target prediction report of compound 5d:    
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Swiss target prediction report of compound 5e 
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3-DIMENSIONAL STRUCTURE OF  DNA-TOPOISOMERASE  
(Protein ID No: rcsb pdb 1JY 1) 
 
 
 
HYBRID-5a 
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HYBRID-5b 
 
 
 
 
 
HYBRID-5c 
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HYBRID-5d 
 
 
 
 
 
HYBRID-5e 
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TABLE 1: CALCULATION OF BIOACTIVITY SCORE FOR NEWLY DESIGNED 
HETEROCYCLIC COMPOUNDS        
   
COMPOUND GPCR 
LIGAND 
ION 
CHANNEL 
MODULATOR 
KINASE 
INHIBITOR 
NUCLEAR 
RECEPTOR 
LIGAND 
PROTEASE 
INHIBITORS 
ENZYME 
INHIBITORS 
HYBRID-5a -0.42 -0.43 0.66 -0.76 -0.66 -0.45 
HYBRID-5b -0.37 -0.36 -0.62 -0.65 -0.60 -0.38 
HYBRID-5c -0.42 -0.42 -0.74 -0.74 -0.73 -0.48 
HYBRID-5d -0.51 -0.62 -0.89 -0.90 -0.89 -0.53 
HYBRID-5e -0.51 -0.60 -0.81 -0.90 -0.78 -0.47 
          
TABLE 2: CALCULATION OF PHYSIOCHEMICAL PROPERTIES FOR NEWLY 
DESIGNED HETEROCYCLIC COMPOUNDS      
  
COMPOUND miLog P 
 
TPSA 
 
MW 
 
nON 
 
nOHNH 
 
nviola 
 
nrot 
 
Volu 
 
HYBRID-5a 3.97 54.77 375.50 5 2 0 4 339.91 
HYBRID-5b 5.06 54.77 403.56 5 2 1 5 373.30 
HYBRID-5c 4.18 54.77 395.92 5 2 0 4 336.88 
HYBRID-5d 2.80 67.91 351.44 6 2 0 4 304.92 
HYBRID-5e 3.44 54.77 367.50 5 2 0 4 314.16 
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TABLE 3: POTENTIAL BINDING  SITES OF THE COMPOUND  
 
S.NO COMPOUND POTENTIAL BINDING SITES 
1. HYBRID-5a Leu189, Gln201,Asn203, Phe202, His280, Leu269, 
Leu268, Leu323, Val277, Leu539, Val278, Ile279. 
2. HYBRID-5b Ile185, Leu189, Ile188, Gln201, Phe202, His280, 
Leu268, Leu323, Phe319, Leu354, Val277, Leu539, 
Val278, Ile279. 
3. HYBRID-5c Ile185, Leu189, Ile188, Phe202, Leu268, Tyr326, 
Leu323, Val277, Leu539, Val278, Ile279, His280. 
4. HYBRID-5d Gln201, Phe202, Leu268, Leu539, Val278. 
5 HYBRID-5e Pro461, His263, Ala521, Ser518. 
 
                 
TABLE 4: BINDING ENERGIES OF THE COMPOUNDS: 
S. No Compound Binding  Energy (-Ve) 
(Kcal/Mol) 
1. HYBRID-5a -2.87 
2. HYBRID-5b +18.61 
3. HYBRID-5c -2.87 
4. HYBRID-5d +18.61 
5. HYBRID-5e +18.61 
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TABLE 5: INHIBITION CONSTANT OF THE NEWLY DESIGNED COMPOUNDS 
 
In addition, two other parameters like inhibition constant (Ki) and intermolecular 
energy were also determined. As shown in Table 5, Compounds showed inhibition 
constant ranging from 7.84mM. The compound hybrids 5a and 5c  (7.84mM) 
showed the lowest inhibition constant. Inhibition constant is directly proportional to 
binding energy. Thus, the DNA Topoisomerase inhibitory activity of the compounds 
was proved using molecular simulations. As shown in Table 5, the compounds 
hybrid 5a and 5c showed lesser intermolecular energy  (-3.37kcal/mol). This result 
further indicates that compound hybrid 5a and 5c have better and stronger DNA 
Topoisomerase inhibitory activity. 
S.No Parameters Hybrid-5a Hybrid-5b Hybrid-5c Hybrid-5d Hybrid-5e 
1. Rank 1_1 1_1 1_1 1_1 1_1 
2. Binding Energy -2.87 18.61 -2.87 18.61 18.61 
3. Inhibition Constant (Ki) 7.84mM Unavaila
ble 
7.84mM Unavaila
ble 
Unavaila
ble 
4. Intermolecular Energy -3.37 17.85 -3.37 17.85 17.85 
5. Internal Energy -0.11 -0.43 -0.11 -0.43 -0.43 
6. Torsional Energy 0.55 0.82 0.55 0.82 0.82 
7. Unbound Extended 
Energy 
-0.06 -0.36 -0.06 -0.36 -0.36 
8. Cluster RMS 0.0 0.0 0.0 0.0 0.0 
9. Ref RMS 64.52 79.9 64.52 79.9 79.9 
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EVALUATION OF IN-VITRO  ANTI-CANCER ACTIVITY BY MTT ASSAY METHOD 
PRINCIPLE:  
 MTT, a yellow tetrazole, is reduced to purple formazan in living cells. A solubilization 
solution usually either dimethyl sulfoxide, an acidified ethanol solution, or a solution of the 
detergent sodium dodecyl sulfate in diluted hydrochloric acid is added to dissolve the 
insoluble purple formazan product into a coloured solution. The absorbance of this colored 
solution can be quantified by measuring at a certain wavelength (usually between 500 and 
600 nm) by a spectrophotometer. The degree of light absorption depends on the solvent.
 
 
 Tetrazolium dye reduction is dependent on NAD(P)H-dependent oxido reductase 
enzymes largely in the cytosolic compartment of the cell. Therefore, reduction of MTT and 
other tetrazolium dyes depends on the cellular metabolic activity due to NAD(P)H flux. Cells 
with a low metabolism such as thymocytes and splenocytes reduce very little MTT. In 
contrast, rapidly dividing cells exhibit high rates of MTT reduction. It is important to keep in 
mind that assay conditions can alter metabolic activity and thus tetrazolium dye reduction  
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without affecting cell viability. In addition, the mechanism of reduction of tetrazolium 
dyes, i.e. intracellular (MTT) vs. extracellular (WST-1), will also determine the amount of 
product 
Kit Components  
MTT Reagent - 25ml 
Detergent reagent - 2 X 125ml     
     
Procedure:            
  The MTT Reagent is ready to use and stable at 4°C in the dark for up to 
eighteen months, provided there is no contamination. Care should be taken not to 
contaminate the MTT Reagent with cell culture medium during pipetting. We recommend 
that the appropriate volume required for each experiment be removed and aseptically 
placed into a separate clean tube and the stock bottle returned to 4°C in the dark. . 
                  The Detergent Reagent is supplied ready to use. If the Detergent Reagent has 
been stored at 4°C, warm the bottle for 5 minutes at 37°C then mix by inverting gently to 
avoid frothing. The detergent is stable for up to eighteen months at room temperature.  
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Equipment and Materials Required:        
              
Microtiter plate reader with 650- and 570-nm 
Filters 
Microtiter plate (flat-bottomed) 
Inverted microscope Sterile tubes (5 mL) 
Multi-channel pipette Serological pipettes 
37°C incubator Sterile pipette tips 
Laminar flow hood  
 
BASIC PROTOCOL: 
If you are familiar with the procedure and know the cell count to use in your specific assay, 
you may follow this basic protocol.        
              
STEP ACTION 
1. Plate cells at 1,000 to 100,000 per well. 
2. Incubate for 6 to 24 hours. 
3. Add 10 μL MTT Reagent. 
4. Incubate for 2 to 4 hours until purple precipitate is visible. 
5. Add 100 μL Detergent Reagent. 
6. Leave at room temperature in the dark for 2 hours. 
7. Record absorbance at 570 nm. 
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DETERMINING OPTIMAL CELL COUNTS 
       Use the protocol below to determine the optimal cell count and incubation period for 
your cell line. This determination should only have to be done once for each cell type. The 
data will be used thereafter in your experimental system following the protocol. 
 
STEP ACTION 
1. Harvest suspension cells by centrifugation. Adherent cells should be 
released from their substrate by trypsinization or scraping. 
2. Re-suspend cells at 1 x 106 per ml. 
3. Prepare serial dilutions of cells in culture medium from 1 x 106 to 1 x 103 
cells per ml. 
4. Plate out, in triplicate, 100 μl of the dilutions into wells of a microtiter 
plate. 
5 Include three control wells of medium alone to provide the blanks for 
absorbance readings. 
6. Incubate the cells under conditions appropriate for the cell line for 6 to 48 
hours (to recover from handling). The time required will vary but 12 hours 
to overnight is sufficient for most cell types 
7. Add 10 μl of MTT Reagent to each well, including controls. 
8. Return plate to cell culture incubator for 2 to 4 hours. 
9. Periodically view the cells under an inverted microscope for presence of 
intracellular punctate purple precipitate 
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10. When the purple precipitate is clearly visible under the microscope add 
100 μl of Detergent Reagent to all wells, including controls. Swirl gently 
do not shake. 
11. Leave plate with cover in the dark for 2 to 4 hours or overnight at room 
temperature. 
12. Remove plate cover and measure the absorbance in each well, including 
the blanks, at 570 nm in a microtiter plate reader. [Absorbances can be 
read with any filter in the wavelength range of 550 - 600 nm. The 
reference wavelength should be higher than 650 nm. The blanks should 
give values close to zero (+/- 0.1).] 
13. If the readings are low return the plate to the dark for longer incubation. 
14. Determine the average values from triplicate readings and subtract the 
average value for the blank. Plot absorbance against number of cells/mL. 
The number of cells to use in your assay should lie within the linear 
portion of the plot and yield an absorbance of 0.75 - 1.25. 
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DATA INTERPRETATION 
The plot of the data obtained in Step 14 on page 3 (absorbance against number of 
cells) should provide a curve with a linear portion. The optimal number of cells for the assay 
should fall within the linear portion of the curve and give an absorbance value between 
0.75 and 1.25. Then both stimulation and inhibition of cell proliferation can be measured. 
To run an assay, select an optimal cell number and follow the MTT Cell Proliferation Assay 
steps 4 to 13 (page 3) using your experimental system, plating in triplicate. Assays will 
include: 
a) Blank wells containing medium only 
b) Untreated control cells 
c) Test cells treated with the substance to be assayed 
If more than 100 μl of medium is used per well, increase the amount of MTT Reagent 
accordingly; 
e.g., for 250 μl of medium use 25 μl of MTT Reagent. 
         Absorbance values that are lower than the control cells indicate a reduction in the rate 
of cell proliferation. Conversely a higher absorbance rate indicates an increase in cell 
proliferation. Rarely, an increase in proliferation may be offset by cell death; evidence of cell 
death may be inferred from morphological changes.      
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HOURS  AVERAGE VALUE  
 
 
 
 
 
 
 
     24 
COMPOUND VARIOUS CONCENTRATION (µg) CONTROL 
5 25 50 75  
Hybrid 5a 0.781 0.733667 0.711 0.698333 0.796667 
PERCENTAGE 98.04 92.01 89.25 87.62 100 
Hybrid 5b 0.793333 0.786 0.742333 0.735 0.796667 
PERCENTAGE 99.55 98,67 93.14 92.26 100 
Hybrid 5c 0.789 0.7686 0.71667 0.722333 0.796667 
PERCENTAGE 99.04 96.40 89.88 90.63 100 
Hybrid 5d 0.762 0.756 0.722 0.609 0.796667 
PERCENTAGE 95.65 94.90 90.63 76.44 100 
Hybrid 5e 0.841667 0.839 0.817 0.783333 0.796667 
PERCENTAGE 105.57 105.32 102.56 98.29 100 
 
 
 
 
 
      48 
Hybrid 5a 1.050667 0.973667 0.961333 0.954 1.112 
PERCENTAGE 94.42 87.5 86.42 85.79 100 
Hybrid 5b 1.112333 1.086 1.031667 1.003667 1.112 
PERCENTAGE 100.02 97.66 92.71 90.19 100 
Hybrid 5c 1.106667 1.089333 1.077667 1.051333 1.112 
PERCENTAGE 99.46 97.93 96.85 94.51 100 
Hybrid 5d 1.052 1.048 1.027667 1.023 1.112 
PERCENTAGE 94.60 94.24 93.35 91.99 100 
Hybrid 5e 1.177 1.124667 1.106333 1.086 1.112 
PERCENTAGE 105.84 101.07 99.46 97.66 100 
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Compound 5a:         
     
 
 
Compound 5b:     
  
               
  
 
 
0.6
0.65
0.7
0.75
0.8
0.85
24h 
24h
80
85
90
95
100
105
24h 
24h
85
90
95
100
105
24H 
24H
0.7
0.75
0.8
0.85
24H 
24H
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 Compound 5c:        
   
   
             
 Compound 5d:          
  
             
                  
 
 
0.65
0.7
0.75
0.8
0.85
24H 
24H
80
85
90
95
100
105
24H 
24H
0
0.2
0.4
0.6
0.8
1
24H 
24H
0
20
40
60
80
100
120
24H 
24H
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Compound 5e:           
        
   
  
  Compound 5a:                                                
     
 
 
 
0.74
0.76
0.78
0.8
0.82
0.84
0.86
control 5µM 25µM 50µM 75µM
24H 
24H
94
96
98
100
102
104
106
108
24H 
24H
0.85
0.9
0.95
1
1.05
1.1
1.15
48H 
48H
75
80
85
90
95
100
105
control 5µM 25µM 50µM 75µM
48H 
48H
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Compound 5b:           
           
 
                
Compound 5c:           
                         
   
 
 
 
 
0.9
0.95
1
1.05
1.1
1.15
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    RESULT: 
COMPARISION OF CONTROL WITH COMPOUNDS                   
PERCENTAGE OF CELL VIABILITY        
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Compound 5c:                                                                                                                              
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Compound 5e:                               
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SUMMARY AND CONCLUSION 
The present work deals with the green synthesis, characterization, molecular 
docking and anti-cancer activity of new series of 1,2,3-triazolyl 
dihydropyrimidine-2-thione hybrids. 
The study comprises of: 
            Designed the lead molecule of and 1,2,3-triazolyl dihydropyrimidine-2-thione 
hybrids assessed ADMET property. 
Synthesis of the title compounds by appropriate methods. 
Determination of physical properties such as solubility, melting point and TLC. 
Characterise the structures of synthesized compounds by IR, 1HNMR and Mass 
spectra. 
Evaluation of the synthesized compounds for their in-vitro anti-cancer activity. 
 
 The compounds were synthesized by reaction between 1,2,3-triazolyl 
chalcone and aromatic aldehydes in the presence of 50% aqueous 
sodium hydroxide grinding 4-7 minutes. Then the above product treated 
with thiourea 10% potassium hydroxide and water reflux to form 1,2,3-
triazolyl dihydropyrimidine-2-thione hybrids. 
 The method had been optimized to synthesis for the synthetic compounds. 
 The compounds were synthesized by appropriate method. 
 The synthesized compounds were purified by TLC. 
 The synthesized compounds were confirmed by FT-IR, 1H NMR,MASS 
Spectroscopy. 
 The IR data showed relevant bands for the functional groups present in 
the synthesized compounds. 
 The 1H NMR also showed relevant proton peaks for all the synthesized 
compounds. 
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 The molecular weights of the compounds were done by MASS 
Spectrocopy. 
 All spectral data coincides with the assigned structure of synthesized 
compounds. 
 The synthesized compounds are analyzed with various steps of molecular 
docking studies and finally concluded for the activity.   
 The synthesized compounds were screened for in-vitro anti-cancer 
activity. 
  In-vitro anti-cancer activity: 
                   All the synthesized compounds exposed anti-cancer activity by MTT assay 
method. 
                  The synthesized compounds HYBRID-5a, HYBRID-5c are show good anti-
cancer activity. HYBRID-5b, HYBRID-5d, HYBRID-5e, shown very poor anti-cancer 
activity.    
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